48 reports of this reaction
2.2% of all DIPHENHYDRAMINE HYDROCHLORIDE, ZINC ACETATE reports
#7 most reported adverse reaction
PRODUCT DOSE OMISSION ISSUE is the #7 most commonly reported adverse reaction for DIPHENHYDRAMINE HYDROCHLORIDE, ZINC ACETATE, manufactured by Major Pharmaceuticals. There are 48 FDA adverse event reports linking DIPHENHYDRAMINE HYDROCHLORIDE, ZINC ACETATE to PRODUCT DOSE OMISSION ISSUE. This represents approximately 2.2% of all 2,218 adverse event reports for this drug.
Patients taking DIPHENHYDRAMINE HYDROCHLORIDE, ZINC ACETATE who experience product dose omission issue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT DOSE OMISSION ISSUE is a less commonly reported adverse event for DIPHENHYDRAMINE HYDROCHLORIDE, ZINC ACETATE, but still significant enough to appear in the safety profile.
In addition to product dose omission issue, the following adverse reactions have been reported for DIPHENHYDRAMINE HYDROCHLORIDE, ZINC ACETATE:
The following drugs have also been linked to product dose omission issue in FDA adverse event reports:
PRODUCT DOSE OMISSION ISSUE has been reported as an adverse event in 48 FDA reports for DIPHENHYDRAMINE HYDROCHLORIDE, ZINC ACETATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT DOSE OMISSION ISSUE accounts for approximately 2.2% of all adverse event reports for DIPHENHYDRAMINE HYDROCHLORIDE, ZINC ACETATE, making it a notable side effect.
If you experience product dose omission issue while taking DIPHENHYDRAMINE HYDROCHLORIDE, ZINC ACETATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.